TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06096493

Intervention type: PROCEDURE
Intervention: curative surgery for cancer rectum
Description: Curative surgery for cancer rectum.
Study: NCT01085851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine 1% lotion
Description: Small amount applied over the lesion twice a day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexchlorpheniramine 1% cream
Description: Small amount applied over the lesion twice a day for 7 days
Study: NCT05973110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: In each of the 12 visits, participants will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for about 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: In each of the 12 visits, participants will complete exercises in virtual reality will complete exercises in virtual reality for two sessions of about 15 minutes separated by a break of 5 to 10 minutes. Participants then engage in a bridging conversation with study staff for around 10 to 15 minutes. More details about each condition will be added after study completion to protect the blinding of our participants.
Study: NCT05488392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia with intrajugular cooling
Description: Hypothermia with intrajugular cooling will be applied after successful recanalization of the culprit internal carotid artery/middle cerebral artery. The perfusion rate will be set at 30 ml/min. Low temperature saline will be infused into the internal jugular vein for 10 min, 15 min, 20 min, 25 min, and 30 min successively.
Study: NCT05173259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G05
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G05
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.
Study: NCT06574893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: physical exercise
Study: NCT06575101

Intervention type: PROCEDURE
Intervention: Target Temperature Management Treatment
Description: Target Temperature Management Treatment

Intervention type: PROCEDURE
Intervention: Target Temperature Management Treatment
Description: Target Temperature Management Treatment
Study: NCT06495476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba extract 50 dropping pills
Description: Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant
Description: Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance.~Size: 10 mg analog ingredient/pill.
Study: NCT06211205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized 3D printed nostril retainer combined with lip taping
Description: the infants will receive a customised nostril retainer appliance to enhance the nasal esthetics combined with lip tape to approximate the labial and alveolar segments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lip taping
Description: the infants will receive lip tape to approximate the labial and alveolar segments
Study: NCT05596370

Intervention type: DIAGNOSTIC_TEST
Intervention: cell free DNA in blood and urine, metabolite/microbiome in urine and stool
Description: cell free DNA in blood and urine, metabolite/microbiome in urine and stool

Intervention type: DIAGNOSTIC_TEST
Intervention: cell free DNA in blood and urine, metabolite/microbiome in urine and stool
Description: cell free DNA in blood and urine, metabolite/microbiome in urine and stool
Study: NCT05188469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-COVID-003
Description: Subjects will receive one, two or three single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-003 0.5mL (mRNA 100μg)~Route of administration: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-COVID-001
Description: Subjects will receive one, two or three single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment at a ratio of 1:1 (Phase 1: n=10, Phase 2a: 50 per treatment)~EG-COVID-001 0.5mL (mRNA 200μg)~Route of administration: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A: EG-COVID
Description: Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 0.5mL (mRNA 400μg)~Route of administration: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B: EG-COVID
Description: Subjects will receive two single IM vaccination(s), 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVID 1mL (mRNA 800μg)~Route of administration: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C: EG-COVARo
Description: Subjects will receive two single IM vaccinations, 3 weeks apart, the subjects will be enrolled to treatment~Component Description (per dose):~EG-COVARo 0.5mL (mRNA 800μg)~Route of administration: Intramuscular injection
Study: NCT06516640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Academy
Description: Educational materials as well as online sessions with diabetes educators.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Education
Description: Standard of care receives general education about diabetes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Education
Description: Standard of care receives general education about diabetes.
Study: NCT05277571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCB1381
Description: UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.
Study: NCT06237205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: a highly selective PARP1 and PARP2 inhibitor
Study: NCT05173259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G05
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G05
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G05
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G05
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 5%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G15
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G15
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G15
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G15
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G15
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G15
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 15%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G25
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G25
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G25
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G25
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G25
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: G25
Description: The participant will be asked to chew the two-coloured chewing gum changing the side in 25%.
Study: NCT05024578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DREEM2
Description: Closed-loop EEG monitoring and auditory stimulation in which 100ms pulses of pink noise are delivered on the ascending phase of slow oscillations during N3 sleep.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: EEG monitoring with the same headband as in the DREEM2 intervention, but without any sound stimulation.
Study: NCT05016778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPRC5D-CAR-T
Description: After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.
Study: NCT05182671

Intervention type: OTHER
Intervention: Scales and measurements for bladder and bowel dysfunction, pelvic angle, proximal hip strength, femoral hip anteversion
Description: Assessments Children whose physical examination has been completed and diagnosed with BBD will be evaluated with following assessments.~Demographic Data Form Questionnaire Forms Dysfunctional Voiding and Incontinence Scoring System Bladder Diary Bowel Diary EMG-uroflowmetry Ultrasonography~Post Voiding Residual Measurement:~Bladder wall thickness~Pelvic Floor Muscle Activation Measurement:~Pelvic Floor Muscle Strength Assessment:~Hip agonist-antagonist muscle ratios Pelvic angle measurement Femoral anteversiyon angle measurement~Femoral internal and external rotation angle:
Study: NCT05530213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D gait analysis on the GRAIL
Description: 3D gait anlysis performed on an instrumented treadmill (GRAIL, Motek Medical)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D gait analysis on the GRAIL
Description: 3D gait anlysis performed on an instrumented treadmill (GRAIL, Motek Medical)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D gait analysis on the GRAIL
Description: 3D gait anlysis performed on an instrumented treadmill (GRAIL, Motek Medical)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight and height
Description: The subject's body weight and height will be assessed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight and height
Description: The subject's body weight and height will be assessed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight and height
Description: The subject's body weight and height will be assessed
Study: NCT06495294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole Blood
Description: 2 units of whole blood administered by Ornge AAS

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBC + plasma
Description: 2 units of RBC + 2 units of plasma administered by Ornge AAS
Study: NCT04938245

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: Intraoperatively, stimulation at 12 Hz will be performed as the leads are moved into the targeted position. Amplitude will be increased to 15 mA maximum total until a response is seen on any electrode and held for 10 seconds. Stimulation and recording will be performed using the Neuralynx stim/record system.~Post-operatively, the electrodes will be tested for impedance by the clinical system and then they will be connected to the Neuralynx stim/record system. Electrode stimulation patterns will be applied with increasing amplitude until ECAPs responses are seen on recording electrodes. 42 Hz stimulation will be performed with an amplitude sweep of 0mA-10mA. At each amplitude, stimulation will be applied for 4 seconds followed by 2 seconds of rest. Pulse width will be varied from 30-450 microseconds to test effective amplitude. Bursting stimulation will be applied to detect differences in ECAPs as above.
Study: NCT06533228

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI) or Magnetic Resonance Enterography (MRE)
Description: Abbreviated magnetic resonance enterography (MRE) imaging to detect active inflammation in patient's with known Crohn's Disease.
Study: NCT06315556

Intervention type: DRUG
Intervention: Aflibercept (Eylea)
Description: Eylea 40 mg/mL solution for injection in pre-filled syringe.
Study: NCT06077487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Injectable Product
Description: Given intramuscularly (IM)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning and Purpose therapy
Description: In-person sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning and Purpose therapy
Description: In-person sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO or IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO or IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires will be given over the course of the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires will be given over the course of the study
Study: NCT06395662

Intervention type: OTHER
Intervention: Observational
Description: Search for biomarkers

Intervention type: OTHER
Intervention: Observational
Description: Search for biomarkers

Intervention type: OTHER
Intervention: Observational
Description: Search for biomarkers

Intervention type: OTHER
Intervention: Observational
Description: Search for biomarkers

Intervention type: OTHER
Intervention: Observational
Description: Search for biomarkers
Study: NCT04791449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Description: Medically-supervised participation in 2-3 exercise sessions per week over 12-wk study period. Exercise conducted in the cardiac rehabilitation program.
Study: NCT06574490

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofunctional therapy (+)
Description: A series of myofunctional exercises performed in 10-20 sessions over 6 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofunctional therapy (-)
Description: NO exercises; A series of myofunctional exercises performed in 10-20 sessions over 6 months is delayed by 1 year
Study: NCT03945955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05589688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Subjects will receive a single dose of 5 mg/kg infused over 1 hour. Then, 13 blood samples after placement of a catheter, and 4 urine samples will be taken over the 12 hours following the start of administration
Study: NCT04917523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Description: 0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Description: 0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen
Study: NCT06329349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks, 3 times a week of progressive endurance aerobic exercise (150 to 400kcal AEE per session)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercise + Diet
Description: 12 weeks, 25% caloric reduction, based on PMID: 37069434
Study: NCT05170048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-301
Description: The investigation drug, EG-301 Tablets 150mg, is for oral use.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AREDS2 supplements
Description: AREDS2 supplement is the stand of care

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AREDS2 supplements
Description: AREDS2 supplement is the stand of care
Study: NCT04917523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Description: 0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Description: 0.5 mL per dose, containing 6.5U inactivated SARS-CoV-2 antigen
Study: NCT06380114

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication
Description: Practice personnel (providers and nurses) receive training in communication about HPV vaccination via an online learning module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication
Description: Practice personnel (providers and nurses) receive training in communication about HPV vaccination via an online learning module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing Orders
Description: Practice personnel (providers and nurses) receive training in the implementation of standing orders for HPV vaccination via an online learning module and meetings with the study team.
Study: NCT06025565

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Experience Measures
Description: Patient reported outcomes measures, quantitative sensory testing, and physical examination measures.
Study: NCT04593433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Museum virtual guided tours
Description: The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 5 participants. They meet online one time per week for a 20 to 25 min of a visit tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
Study: NCT05738057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg on day1 of every 3 weeks, starting on day1 of cycle1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: 1000mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: 25mg/m2 on day1 \& day8 of every 3 weeks, starting on day1 of cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin-Eluting Beads
Description: used for D-TACE